Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of Trametinib in
Non‐V600
BRAF
Mutant Melanoma: A Phase II Study
Authors
Keywords
-
Journal
ONCOLOGIST
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-04-17
DOI
10.1002/onco.13795
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
- (2020) Douglas B. Johnson et al. CLINICAL CANCER RESEARCH
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- (2019) Christian Menzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
- (2019) Thomas Botton et al. Cell Reports
- Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanoma
- (2018) Matthew Dankner et al. CLINICAL CANCER RESEARCH
- Long-Term Outcomes in Patients With BRAF V600–Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib
- (2018) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF fusions identified in melanomas have variable treatment responses and phenotypes
- (2018) Jacqueline A. Turner et al. ONCOGENE
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Clinicopathological features and clinical outcomes associated withTP53andBRAFNon-V600mutations in cutaneous melanoma patients
- (2016) Dae Won Kim et al. CANCER
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
- (2015) Zhan Yao et al. CANCER CELL
- The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy
- (2015) Jeffrey S. Ross et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
- (2015) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib
- (2013) Rachael Anforth et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition
- (2013) K. E. Hutchinson et al. CLINICAL CANCER RESEARCH
- BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors
- (2012) Kimberly Brown Dahlman et al. Cancer Discovery
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now